<DOC>
	<DOC>NCT01679847</DOC>
	<brief_summary>The purpose of this study is to elucidate the pharmacokinetics and the blood-brain barrier penetration of the elemene.</brief_summary>
	<brief_title>Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.</brief_title>
	<detailed_description />
	<criteria>histopathological or cytopathology diagnosis of malignancy heart, liver and renal function is normal Expected survival time is more than 3 months Signed informed consent exclusion Criteria: non cancer patient accepted elemene administration in 1 month Expected survival time is less than 3 months no Signed informed consent heart, liver and renal function is abnormal</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Elemene</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Blood-brain barrier</keyword>
</DOC>